ALKS
Alkermes plc
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Neutral
+11/100
Last price
41.65
▼ 1.11 (2.60%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
42.76
Day high
42.71
Day low
41.24
Volume
1.55M
Market cap
$6.99B
P/E (TTM)
109.61
52W range
27.00 – 55.67
Trailing performance
Returnvs SPY
1W
+2.08%
+0.1%
1M
-9.65%
-10.8%
3M
-23.28%
-27.8%
6M
+26.14%
+8.0%
YTD
+48.86%
+34.6%
1Y
+34.10%
+17.7%
3Y
+48.70%
-33.6%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on ALKS open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+19.28K
Net buying
Buy transactions
17
144.72K shares
Sell transactions
14
125.44K shares
Net transactions
+31
Buys less sells
Sell : buy shares
0.9 : 1
Mixed
Insider-held shares
2.35M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 3, 26 | GAFFIN DAVID JOSEPH Officer |
SELL | 2.03K | $97.65K | Direct |
| Sep 1, 26 | HOPKINSON CRAIG C Officer |
CONVERSION | 5.00K | $122.95K | Direct |
| Sep 1, 26 | HOPKINSON CRAIG C Officer |
SELL | 9.00K | $422.87K | Direct |
| Aug 17, 26 | NICHOLS CHRISTIAN TODD Officer |
SELL | 7.58K | $372.94K | Direct |
| Aug 3, 26 | SNYDERMAN NANCY LYNN Director |
CONVERSION | 44.47K | $2.08M | Direct |
| Aug 3, 26 | HOPKINSON CRAIG C Officer |
CONVERSION | 5.00K | $122.40K | Direct |
| Aug 3, 26 | GAFFIN DAVID JOSEPH Officer |
SELL | 2.03K | $98.81K | Direct |
| Aug 3, 26 | HOPKINSON CRAIG C Officer |
SELL | 9.00K | $437.22K | Direct |
| Aug 3, 26 | SNYDERMAN NANCY LYNN Director |
SELL | 44.47K | $2.24M | Direct |
| Jul 6, 26 | GAFFIN DAVID JOSEPH Officer |
SELL | 2.03K | $109.90K | Direct |
| Jul 1, 26 | HOPKINSON CRAIG C Officer |
CONVERSION | 5.00K | $96.70K | Direct |
| Jul 1, 26 | HOPKINSON CRAIG C Officer |
SELL | 9.00K | $463.62K | Direct |
| Jun 12, 26 | WRIGHT CHRISTOPHER I Director |
SELL | 2.00K | $90.20K | Direct |
| Jun 4, 26 | GAFFIN DAVID JOSEPH Officer |
SELL | 2.03K | $87.56K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BROWN IAIN MICHAEL |
Chief Financial Officer | 148.20K | Conversion of Exercise of derivative security |
COOKE SHANE M |
Director | 106.68K | Conversion of Exercise of derivative security |
GAFFIN DAVID JOSEPH |
Officer | 223.42K | Sale |
HOPKINSON CRAIG C |
Officer | 65.39K | Conversion of Exercise of derivative security |
JACKSON BLAIR CURTIS |
Chief Operating Officer | 241.31K | Conversion of Exercise of derivative security |
MCKEON BRIAN P |
Director | 48.54K | Conversion of Exercise of derivative security |
NICHOLS CHRISTIAN TODD |
Officer | 102.19K | Sale |
POPS RICHARD F |
Chief Executive Officer | 1.38M | Stock Award(Grant) |
SNYDERMAN NANCY LYNN |
Director | 36.18K | Conversion of Exercise of derivative security |
WILSON FRANK ANDERS |
Director | 35.75K | Conversion of Exercise of derivative security |
Fundamentals
Market cap$6.99B
Enterprise value$7.90B
Revenue (TTM)$1.67B
Gross profit$1.45B
EBITDA$284.93M
Net income$66.12M
EPS (TTM)$0.38
Free cash flow$153.38M
Total cash$656.58M
Total debt$1.57B
Book value / share$10.80
Shares outstanding167.76M
Float155.20M
Short % of float12.52%
Dividend yield0.00%
Beta (5Y)0.27
Valuation & profitability ratios
Trailing P/E109.61
Forward P/E23.03
PEG ratio1.96
Price / sales—
Price / book3.86
EV / revenue4.74
EV / EBITDA27.74
Gross margin87.18%
Operating margin15.50%
Profit margin3.96%
Return on equity3.85%
Return on assets4.20%
Debt / equity86.95
Current ratio2.30
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $1.48B | $1.56B | $1.66B | $1.11B | -5.2% |
| Operating revenue | $1.48B | $1.56B | $1.66B | $1.11B | -5.2% |
| Cost of revenue | $196.46M | $245.33M | $253.04M | $218.07M | -19.9% |
| Gross profit | $1.28B | $1.31B | $1.41B | $893.73M | -2.5% |
| Research & development | $323.96M | $245.33M | $270.81M | $272.70M | +32.1% |
| Selling, general & admin | $701.52M | $645.24M | $689.75M | $590.75M | +8.7% |
| Total operating expense | $1.03B | $891.66M | $996.25M | $899.82M | +15.0% |
| Operating income | $253.96M | $420.64M | $414.12M | -$6.09M | -39.6% |
| Net interest income | $33.03M | $19.87M | $7.82M | -$5.41M | +66.2% |
| Pre-tax income | $291.45M | $443.75M | $421.52M | -$31.13M | -34.3% |
| Tax provision | $49.79M | $71.61M | -$97.64M | $2.02M | -30.5% |
| Net income | $241.66M | $367.07M | $355.76M | -$158.27M | -34.2% |
| Net income to common | $241.66M | $367.07M | $355.76M | -$158.27M | -34.2% |
| Basic EPS | 1.47 | 2.22 | 2.14 | -0.97 | -33.8% |
| Diluted EPS | 1.43 | 2.17 | 2.10 | -0.97 | -34.1% |
| EBIT | $303.73M | $466.33M | $444.55M | -$18.09M | -34.9% |
| EBITDA | $330.89M | $494.86M | $519.48M | $59.77M | -33.1% |
| Basic shares | 164.70M | 165.39M | 166.22M | 163.74M | -0.4% |
| Diluted shares | 168.74M | 169.20M | 169.73M | 163.74M | -0.3% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $388.57M | $291.15M | $457.47M | $292.47M | — | +33.5% |
| Cash & short-term investments | $588.22M | $751.67M | $773.49M | $608.47M | — | -21.7% |
| Accounts receivable | $268.63M | $315.33M | $229.58M | $216.17M | — | -14.8% |
| Inventory | $196.63M | $182.89M | $186.41M | $181.42M | — | +7.5% |
| Total current assets | $1.93B | $1.42B | $1.49B | $1.13B | — | +36.3% |
| Property, plant & equipment | $298.93M | $311.81M | $318.40M | $320.46M | — | -4.1% |
| Goodwill & intangibles | $83.84M | $83.92M | $85.02M | $120.71M | — | -0.1% |
| Total assets | $2.49B | $2.06B | $2.14B | $1.96B | — | +21.0% |
| Total current liabilities | $543.44M | $465.20M | $520.22M | $497.74M | — | +16.8% |
| Current debt | — | — | $3.00M | $3.00M | $3.00M | — |
| Long-term debt | — | — | $287.73M | $290.27M | $292.80M | — |
| Total debt | $70.00M | $75.54M | $372.19M | $379.44M | — | -7.3% |
| Total liabilities | $667.70M | $590.59M | $933.54M | $920.23M | — | +13.1% |
| Retained earnings | -$734.79M | -$976.46M | -$1.34B | -$1.70B | — | +24.7% |
| Shareholder equity | $1.82B | $1.46B | $1.20B | $1.04B | — | +24.2% |
| Working capital | $1.39B | $950.16M | $965.29M | $632.56M | — | +45.8% |
| Net tangible assets | $1.74B | $1.38B | $1.12B | $923.05M | — | +25.7% |
| Shares issued | 181.01M | 176.67M | 172.57M | 168.95M | — | +2.5% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | $241.66M | $367.07M | $355.76M | -$158.27M | -34.2% |
| Depreciation & amortisation | $27.16M | $28.53M | $74.93M | $77.86M | -4.8% |
| Stock-based compensation | $98.72M | $96.64M | $100.91M | $94.25M | +2.2% |
| Change in working capital | $119.12M | -$98.15M | -$36.66M | $12.71M | +221.4% |
| Operating cash flow | $520.75M | $439.12M | $401.35M | $21.04M | +18.6% |
| Capital expenditure | -$40.42M | -$33.48M | -$48.05M | -$38.26M | -20.7% |
| Investing cash flow | $295.50M | -$111.31M | $53.36M | -$64.54M | +365.5% |
| Share buybacks | $0 | -$200.28M | $0 | $0 | +100.0% |
| Financing cash flow | $12.38M | -$494.14M | -$289.71M | -$1.57M | +102.5% |
| Free cash flow | $480.33M | $405.64M | $353.31M | -$17.21M | +18.4% |
| End cash position | $1.12B | $291.15M | $457.47M | $292.47M | +284.6% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | — | $392.91M | $384.55M | $394.19M | $390.66M | $306.51M | — |
| Operating revenue | — | $392.91M | $384.55M | $394.19M | $390.66M | $306.51M | — |
| Cost of revenue | — | $61.58M | $46.21M | $51.59M | $49.46M | $49.20M | — |
| Gross profit | — | $331.33M | $338.34M | $342.59M | $341.20M | $257.31M | — |
| Research & development | — | $103.34M | $93.04M | $81.74M | $77.37M | $71.82M | — |
| Selling, general & admin | — | $264.59M | $187.20M | $171.77M | $170.85M | $171.70M | — |
| Total operating expense | — | $379.61M | $280.23M | $253.51M | $248.22M | $243.52M | — |
| Operating income | — | -$48.28M | $58.10M | $89.08M | $92.98M | $13.79M | — |
| Net interest income | — | -$12.35M | -$147.00K | $11.94M | $11.09M | $10.14M | — |
| Pre-tax income | — | -$61.93M | $60.38M | $100.75M | $104.84M | $25.49M | — |
| Tax provision | — | $4.55M | $11.04M | $17.98M | $17.74M | $3.02M | — |
| Net income | — | -$66.48M | $49.34M | $82.76M | $87.10M | $22.46M | — |
| Net income to common | — | -$66.48M | $49.34M | $82.76M | $87.10M | $22.46M | — |
| Basic EPS | 0.00 | -0.40 | 0.30 | 0.50 | 0.53 | — | +100.0% |
| Diluted EPS | 0.00 | -0.40 | 0.29 | 0.49 | 0.52 | — | +100.0% |
| EBIT | — | -$41.03M | $72.65M | $100.75M | $104.84M | $25.49M | — |
| EBITDA | — | -$21.61M | $76.50M | $108.83M | $112.66M | $32.91M | — |
| Basic shares | 167.03M | 166.20M | 165.33M | 165.09M | 164.96M | — | +0.5% |
| Diluted shares | 173.48M | 166.20M | 169.54M | 168.51M | 168.36M | — | +4.4% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $351.55M | $388.57M | $616.45M | $521.20M | $399.81M | -9.5% |
| Cash & short-term investments | $511.86M | $588.22M | $1.11B | $1.02B | $884.02M | -13.0% |
| Accounts receivable | $407.63M | $268.63M | $354.39M | $354.91M | $318.70M | +51.7% |
| Inventory | $336.70M | $196.63M | $191.00M | $191.92M | $183.44M | +71.2% |
| Total current assets | $1.36B | $1.93B | $1.74B | $1.64B | $1.48B | -29.6% |
| Property, plant & equipment | $298.83M | $298.93M | $326.11M | $319.93M | $316.33M | -0.0% |
| Goodwill & intangibles | $2.38B | $83.84M | $83.86M | $83.88M | $83.90M | +2,738.8% |
| Total assets | $4.26B | $2.49B | $2.33B | $2.25B | $2.08B | +71.2% |
| Total current liabilities | $599.50M | $543.44M | $474.36M | $505.96M | $443.73M | +10.3% |
| Current debt | $26.50M | — | — | — | — | — |
| Long-term debt | $1.48B | — | — | — | — | — |
| Total debt | $1.58B | $70.00M | $71.60M | $72.68M | $74.10M | +2,159.5% |
| Total liabilities | $2.51B | $667.70M | $596.08M | $628.23M | $570.39M | +275.4% |
| Retained earnings | -$801.27M | -$734.79M | -$784.13M | -$866.90M | -$953.99M | -9.0% |
| Shareholder equity | $1.75B | $1.82B | $1.73B | $1.62B | $1.51B | -3.7% |
| Working capital | $759.14M | $1.39B | $1.27B | $1.13B | $1.04B | -45.2% |
| Net tangible assets | -$628.54M | $1.74B | $1.65B | $1.54B | $1.43B | -136.2% |
| Shares issued | 183.59M | 181.01M | 180.50M | 180.44M | 180.18M | +1.4% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$66.48M | $49.34M | $82.76M | $87.10M | $22.46M | -234.7% |
| Depreciation & amortisation | $19.43M | $3.85M | $8.08M | $7.82M | $7.42M | +405.2% |
| Stock-based compensation | $36.33M | $26.27M | $24.66M | $24.97M | $22.81M | +38.3% |
| Change in working capital | -$160.25M | $91.41M | -$46.38M | $30.76M | $43.34M | -275.3% |
| Operating cash flow | -$165.74M | $170.07M | $101.67M | $150.20M | $98.81M | -197.5% |
| Capital expenditure | -$4.09M | — | -$17.31M | -$13.02M | -$10.11M | — |
| Investing cash flow | -$2.08B | $322.35M | -$6.74M | -$29.21M | $9.10M | -744.3% |
| Share buybacks | -$27.70M | $0 | $0 | $0 | $0 | — |
| Financing cash flow | $1.47B | $10.91M | $315.00K | $405.00K | $747.00K | +13,412.8% |
| Free cash flow | -$169.83M | $170.09M | $84.36M | $137.19M | $88.70M | -199.8% |
| End cash position | $351.55M | $1.12B | $616.45M | $521.20M | $399.81M | -68.6% |
Options analytics
Put / call volume
3.78
Put-heavy session
Put / call open interest
—
Positioning, not flow
Max pain
35.00
-16.0% from spot
ATM implied vol
1.6%
Nearest strike to spot
Skew (10% OTM)
0.0%
Calls bid over puts
Call volume
116
Contracts, this expiry
Put volume
438
Contracts, this expiry
Heaviest call OI
35.00
0 contracts
Heaviest put OI
35.00
0 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | 0.29 | 0.70 | +141.3% |
| Mar 2026 | -0.04 | 0.38 | +1,053.0% |
| Dec 2025 | 0.45 | 0.48 | +7.7% |
| Sep 2025 | 0.39 | 0.65 | +68.5% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 0.25 | 4 | $465.06M | +18.0% |
| Next quarter | 0.09 | 4 | $472.56M | +22.9% |
| Current year | 1.27 | 4 | $1.82B | +23.6% |
| Next year | 1.81 | 4 | $1.94B | +6.5% |
Analyst targets & ownership
Mean target$56.56
High target$83.00
Low target$38.00
Implied upside35.79%
Analyst count18
ConsensusBUY
Strong buy / Buy3 / 11
Hold4
Sell / Strong sell0 / 1
Held by insiders1.40%
Held by institutions107.45%
Institutions holding569
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
41.19
+1.11% from price
SMA 20
43.25
-3.69% from price
SMA 50
46.53
-10.48% from price
SMA 100
46.65
-10.71% from price
SMA 200
39.23
+6.16% from price
EMA 12
42.12
-1.10% from price
EMA 26
43.74
-4.78% from price
EMA 50
45.20
-7.85% from price
RSI (14)
38.7
Neutral
MACD (12,26,9)
-1.63
Hist 0.10
ATR (14)
1.57
3.78% of price
Realised vol 30D
32.2%
Annualised
Bollinger upper
47.80
20, 2σ
Bollinger lower
38.69
20, 2σ
50 / 200 cross
Golden
46.53 vs 39.23
Trend bias
Above 200
+6.16%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.80
Less volatile than market
Correlation to SPY
0.26
Largely independent
Realised vol 30D
32.2%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-27.3%
Peak to trough
Max drawdown 5Y
-33.1%
Peak to trough
ATR 14
1.57
3.78% of price
Beta (reported)
0.27
5Y monthly, from filing
Short interest
Shares short
15.16M
Prior 14.76M
Change vs prior
+2.7%
Shorts adding
% of float
12.52%
Elevated
% of shares out
9.03%
Against total outstanding
Days to cover
11.2
Crowded exit
Float
155.20M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 22, 26 | RBC Capital | MAINTAINED | Outperform | Outperform |
| Sep 22, 26 | Baird | MAINTAINED | Outperform | Outperform |
| Sep 21, 26 | Needham | MAINTAINED | Buy | Buy |
| Jul 29, 26 | JP Morgan | MAINTAINED | Neutral | Neutral |
| Jul 29, 26 | Baird | MAINTAINED | Outperform | Outperform |
| Jul 28, 26 | Piper Sandler | MAINTAINED | Overweight | Overweight |
| Jul 20, 26 | Stifel | MAINTAINED | Buy | Buy |
| Jul 13, 26 | Needham | MAINTAINED | Buy | Buy |
| Jul 2, 26 | Mizuho | MAINTAINED | Outperform | Outperform |
| Jun 29, 26 | Wells Fargo | MAINTAINED | Overweight | Overweight |
| Jun 29, 26 | B of A Securities | DOWNGRADE | Neutral | Underperform |
| Jun 24, 26 | Needham | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split2:1
Split dateMay 15, 2000
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-09-21
Corporate Changes & Voting Matters
8-K · 2026-09-16
Corporate Changes & Voting Matters
8-K · 2026-08-12
Corporate Changes & Voting Matters
8-K/A · 2026-08-03
Periodic Financial Reports
10-Q · 2026-07-28
Corporate Changes & Voting Matters
8-K · 2026-07-08
Corporate Changes & Voting Matters
8-K · 2026-06-15
Corporate Changes & Voting Matters
8-K · 2026-05-20
Headlines
Why Baird Sees Promising Growth Potential in Alkermes plc (ALKS)
Insider Monkey · 2d ago
LQDA versus ALKS: Which Biotech Stock Is the Better Buy Now?
Zacks · 7d ago
Alkermes (ALKS) Reports Early ADHD Drug Results. Can a Larger Trial Show it Works?
Insider Monkey · 11d ago
Why Alkermes (ALKS) Is Down 6.0% After First ADHD Data For Orexin Agonist ALKS 7290
Simply Wall St. · 14d ago
Alkermes ADHD Data Boosts Confidence in ALKS7290, Orexin Pipeline, RBC Says
MT Newswires · 15d ago
Alkermes Posts Positive Data From Phase I ADHD Study on ALKS 7290
Zacks · 15d ago
An orexin drug’s ‘proof-of-concept’ in ADHD; Cue’s ‘unwarranted’ share slide
BioPharma Dive · 15d ago
How Alkermes Used Its Narcolepsy Playbook In ADHD — And Seemingly Won
Investor's Business Daily · 16d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.